Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
SAB Biotherapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
SABS
Nasdaq
2834
www.sabbiotherapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for SAB Biotherapeutics, Inc.
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
- May 9th, 2025 7:00 am
SAB BIO Reports Full Year 2024 Operating and Financial Results
- Mar 31st, 2025 5:32 am
SAB BIO to Participate in Upcoming Investor Conferences
- Jan 31st, 2025 5:00 am
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
- Jan 28th, 2025 5:00 am
3 Promising US Penny Stocks With At Least $20M Market Cap
- Jan 27th, 2025 1:04 pm
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
- Jan 23rd, 2025 5:00 am
SAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To Consider
- Dec 23rd, 2024 6:04 am
These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts
- Nov 15th, 2024 7:50 am
SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)
- Nov 9th, 2024 7:40 am
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
- Nov 6th, 2024 3:05 pm
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
- Oct 31st, 2024 5:00 am
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely
- Sep 23rd, 2024 8:53 am
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
- Sep 13th, 2024 5:00 am
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
- Sep 9th, 2024 5:00 am
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
- Sep 4th, 2024 5:05 am
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
- Aug 8th, 2024 3:51 pm
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
- Aug 5th, 2024 5:30 am
SAB BIO Appoints Lucy To as Chief Financial Officer
- Jul 31st, 2024 5:30 am
Scroll